Related Experiment Video

Updated: Jun 2, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Role of tumor vascular architecture in drug delivery

Ajit S Narang1, Sailesh Varia

  • 1Bristol-Myers Squibb, Co., One Squibb Dr., PO Box 191, New Brunswick, NJ 08903-0191, USA. ajit.narang@bms.com

Advanced Drug Delivery Reviews
|April 26, 2011
PubMed

Insights

Tumor targeted drug delivery enhances cancer care by improving drug efficacy and reducing side effects. Understanding tumor pathophysiology and vascular architecture is crucial for successful targeted drug delivery.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Tumor targeted drug delivery offers potential benefits for cancer treatment, including reduced non-target toxicities and increased drug efficacy.
  • Effective tumor targeting requires a deep understanding of dynamic tumor pathophysiology, including changes in angiogenic status, cell mass, and extracellular matrix.
  • Overcoming barriers to drug delivery necessitates an appreciation of unique tumor vascular architecture and specific biochemical markers.

Purpose of the Study:

  • To review the critical aspects of tumor vascular architecture relevant to targeted drug delivery.
  • To highlight the challenges and opportunities in exploiting tumor vascular characteristics for enhanced drug delivery.

Main Methods:

  • Literature review focusing on tumor pathophysiology and vascular architecture.
  • Analysis of existing research on drug delivery barriers and targeting strategies.

Main Results:

  • Tumor vascular architecture presents unique challenges for drug penetration and distribution.
  • Dynamic changes within the tumor microenvironment influence drug delivery efficiency.
  • Specific biochemical markers and vascular characteristics can be exploited for targeted delivery.

Conclusions:

  • A comprehensive understanding of tumor vascular architecture is essential for developing effective targeted drug delivery systems.
  • Exploiting the unique features of tumor vasculature is key to overcoming delivery barriers and improving therapeutic outcomes in cancer treatment.

More Related Videos

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research07:26

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research

Published on: September 15, 2023

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...